Gainesville, Fla. – June 22, 2017 — Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, announced today that the company marked the first clinical use of recently approved shoulder, knee and hip replacement systems in Japan this quarter. These surgeries coincide with the series of new product introductions the company has reported in the U.S.
Exactech has gained regulatory approval to introduce additional products from each of its three major product segments to the Japanese market. The first Optetrak Logic® CR knee system was implanted on April 6 at Taketa Medical Association Hospital in Oita. The Novation® Crown Cup acetabular component debuted on April 26 in Ukubo City. The first Exactech total hip replacement surgery in Japan took place on May 16 at the Taketa Medical Association Hospital when a surgeon implanted the Alteon Tapered Wedge Stem along with the Crown Cup. The first Equinoxe Reverse Shoulder system was implanted June 5 at Sano Memorial Hospital.
“Exactech has maintained direct distribution in Japan since 2008 with consistent growth. These new product introductions are important milestones for Exactech in one of our key global markets,” said Exactech Vice President of International Sales and Market Development Daniel Berdat. “We are pleased to expand our offerings with these important innovations to better serve surgeons and patients.”
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at https://www.exac.com.
A current investment profile on Exactech (Nasdaq: EXAC) is available online at https://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at https://www.hawkassociates.com/about/alert.
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.
Executive Vice President of Finance & Chief Financial Officer
Julie Marshall or Frank Hawkins
Priscilla Bennett, Exactech
Vice President, Corporate & Marketing Communication